Clinical Trial

A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 26, 2025 (before its estimated July 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD13-02 in patients with aT1DM
Trial Details
NCT Number NCT07142161
Lead Sponsor Nanjing Bioheng Biotech Co., Ltd.
Conditions Type 1 Diabetes
Enrollment 3 participants
Start Date 2025-07-20
Primary Completion 2026-07-24 (estimated)
Study Completion 2026-12-25 (estimated)
Updated on ClinicalTrials.gov 2025-08-26